Search

Displaying results 5421 - 5430 of 10000 in total
  1. Drug

    Influenza B virus B/Massachusetts/2/2012 recombinant hemagglutinin antigen

    go.drugbank.com/drugs/DB10777
    ApprovedWithdrawn

    Inactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.

  2. Drug

    Influenza A virus A/Switzerland/9715293/2013 (H3N2) recombinant hemagglutinin antigen

    go.drugbank.com/drugs/DB10778
    ApprovedWithdrawn

    Inactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.

  3. Drug

    Influenza A virus A/California/7/2009(H1N1)-like antigen (formaldehyde inactivated)

    go.drugbank.com/drugs/DB10802
    ApprovedWithdrawn

    Inactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.

  4. Drug

    Influenza B virus B/Phuket/3073/2013 live (attenuated) antigen

    go.drugbank.com/drugs/DB11036
    Approved

    Inactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.

  5. Drug

    CP-778875

    go.drugbank.com/drugs/DB19211
    Investigational

    CP-778875 is under investigation in clinical trial NCT00326326 (Effect of CP-778,875 on HDL-C in Subjects With Abnormal Lipid Levels and Type 2 Diabetes.).

  6. Drug

    Nicotinamide riboside

    go.drugbank.com/drugs/DB14933
    ApprovedInvestigationalWithdrawn

    Nicotinamide riboside is under investigation in clinical trial NCT03432871 (Nicotinamide Riboside and Mitochondrial Biogenesis).

  7. Drug

    Ochromycinone

    go.drugbank.com/drugs/DB15644
    Investigational

    Ochromycinone is under investigation in clinical trial NCT01047943 (STA-21 Topical Efficacy on Psoriasis).

  8. Drug

    Carlumab

    go.drugbank.com/drugs/DB12718
    ApprovedWithdrawn

    Carlumab has been used in trials studying the treatment of Cancer and Prostate Cancer.

  9. Drug

    ISA101b

    go.drugbank.com/drugs/DB18694
    Investigational

    ISA101b (peltopepimut-S) is a therapeutic vaccine against the HPV-specific E6/E7 oncoproteins.

  10. Drug

    Trevogrumab

    go.drugbank.com/drugs/DB15159
    Investigational

    and Healthy Adult Men). … Trevogrumab is under investigation in clinical trial NCT02943239 (Study of Safety, Tolerability, and Pharmacokinetics of REGN2477 Alone and in Combination With REGN1033 in Healthy Postmenopausal Women